Results 101 to 110 of about 18,707,175 (333)

Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer

open access: yesMolecular Oncology, EarlyView.
This study employed targeted metabolomic profiling to identify 302 distinct metabolites present in platelet‐rich plasma (PRP), revealing aberrant metabolic profiles amongst individuals diagnosed with colorectal cancer (CRC). Compared to carcinoembryonic antigen (CEA) and cancer antigen 19‐9 (CA199), our metabolite panel showed improved sensitivity ...
Zuojian Hu   +7 more
wiley   +1 more source

Collaborative Design of Controlled Experiments in the Presence of Subject Covariates [PDF]

open access: yesarXiv
We consider the optimal experimental design problem of allocating subjects to treatment or control when subjects participate in multiple, separate controlled experiments within a short time-frame and subject covariate information is available. Here, in addition to subject covariates, we consider the dependence among the responses coming from the ...
arxiv  

D-Optimal designs for a multivariate regression model

open access: yesJournal of Multivariate Analysis, 1992
AbstractConsidered is a linear regression model with a one-dimensional control variable and an m-dimensional response variable y. The components of y may be correlated with known covariance matrix. Let B be the covariance matrix of the Gauss-Markoff estimator for the unknown parameter vector of the model.
Olaf Krafft, Martin Schaefer
openaire   +2 more sources

Inhibition of acyl‐CoA synthetase long‐chain isozymes decreases multiple myeloma cell proliferation and causes mitochondrial dysfunction

open access: yesMolecular Oncology, EarlyView.
Triacsin C inhibition of the acyl‐CoA synthetase long chain (ACSL) family decreases multiple myeloma cell survival, proliferation, mitochondrial respiration, and membrane potential. Made with Biorender.com. Multiple myeloma (MM) is an incurable cancer of plasma cells with a 5‐year survival rate of 59%.
Connor S. Murphy   +12 more
wiley   +1 more source

Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer

open access: yesMolecular Oncology, EarlyView.
mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia   +17 more
wiley   +1 more source

Optimal digitization of 2-d images [PDF]

open access: green, 1984
Lars Nielsen, Kalle Åström, E.I. Jury
openalex   +1 more source

Integration of single‐cell and bulk RNA‐sequencing data reveals the prognostic potential of epithelial gene markers for prostate cancer

open access: yesMolecular Oncology, EarlyView.
Prostate cancer is a leading malignancy with significant clinical heterogeneity in men. An 11‐gene signature derived from dysregulated epithelial cell markers effectively predicted biochemical recurrence‐free survival in patients who underwent radical surgery or radiotherapy.
Zhuofan Mou, Lorna W. Harries
wiley   +1 more source

Optimal BIBD-extended designs [PDF]

open access: yesarXiv, 2019
Balanced incomplete block designs (BIBDs) are a class of designs with v treatments and b blocks of size k that are optimal with regards to a wide range of optimality criteria, but it is not clear which designs to choose for combinations of v, b and k when BIBDs do not exist.
arxiv  

Home - About - Disclaimer - Privacy